CNP-106 is created for treating the underlying autoimmune causes of myasthenia gravis. Credit: Tatiana from Pixabay.

The US Food and Drug Administration (FDA) has granted clearance for the Investigational New Drug (IND) application of Cour Pharmaceuticals to launch a Phase Ib/IIa clinical trial of its investigational therapy, CNP-106, for myasthenia gravis (MG).

The proof-of-concept, randomised, double-blind, placebo-controlled trial is anticipated to commence in the first quarter of next year.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It will evaluate the tolerability, safety, immunogenicity and initial efficacy of CNP-106 in a representative sample of adult MG patients.

CNP-106 is created for treating the underlying autoimmune causes of MG using antigen-specific tolerance induced by the therapy.

Through T-cell reprogramming to boost immune tolerance using T regulatory cells, the therapy could potentially stop and reverse MG. 

See Also:

Cour Pharmaceuticals founder and CEO John Puisis said: “The FDA’s acceptance of our IND application in myasthenia gravis represents Cour’s fourth IND clearance to date and expands our focus deeper into rare and severe autoimmune diseases. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“As we continue to advance our MG programme into the clinic, we look forward to demonstrating clear differentiation to existing approved therapies in durability of response and safety without the need of concomitant immunosuppressive therapies, offering a potentially groundbreaking, disease modifying treatment for patients who suffer the debilitating effects of MG.”

An autoimmune neuromuscular ailment, MG impairs the ability of skeletal muscles to contract by disrupting the communication between motor neurons and muscle fibres.

These muscles control breathing and movement of the body parts such as the face, throat, arms and legs. 

Between 15% to 20% of patients with MG experience at least one myasthenia crisis, as per the National Institute of Neurological Disorders and Stroke.